Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

10:02 AM ET 8-K
M&A Deal Mercantile Bank Corp MBWM

Mercantile Bank M&A Deal with Eastern Michigan Bank

Mercantile Bank Corporation has received regulatory approval from the FDIC and the Michigan Department of Insurance and Financial Services (DIFS) to merge Eastern Michigan Bank into Mercantile Bank. The approval allows for the conversion of Eastern Michigan Bank's twelve offices into Mercantile Bank branches, with the merger expected to close in the first quarter of 2027. This update follows the previously announced definitive agreement between the two Michigan-based banking organizations.

Counterparty
Eastern Michigan Bank
9:45 AM ET 8-K
M&A Deal Viatris Inc VTRS

Viatris Signs $1.69B M&A Deal with Pacira BioSciences, Inc.

Viatris Inc. has completed its acquisition of Pacira BioSciences, Inc. for approximately $1.69 billion in cash. The transaction was executed via a tender offer for $36.50 per share followed by a merger, establishing Viatris as a leader in non-opioid pain management.

Value
$1.69B
Counterparty
Pacira BioSciences, Inc.

“Today marks an important milestone in the execution of our strategy to strengthen our U.S. innovative medicines business. With Pacira now part of Viatris, we are bringing together complementary portfolios, capabilities and expertise to establish a leadership position in non-opioid pain management. We are excited to welcome our new Pacira colleagues as we create new opportunities to make a meaningful difference for patients and accelerate our path to sustained revenue and earnings growth.”

Scott A. Smith, CEO of Viatris
9:43 AM ET 8-K
M&A Deal Pacira BioSciences, Inc. PCRX

Pacira BioSciences M&A Deal with Viatris Inc.

Pacira BioSciences, Inc. completed its merger with Viatris Inc. on November 17, 2026, following a tender offer where Viatris acquired all outstanding shares for $36.50 per share in cash. As a result of the transaction, Pacira has become a wholly owned subsidiary of Viatris and entered into supplemental indentures to address its outstanding 2.125% Convertible Senior Notes due 2029.

Counterparty
Viatris Inc.
9:30 AM ET 8-K
M&A Deal Pulmatrix, Inc. PULM

Pulmatrix M&A Deal with Eos SENOLYTIX, Inc.

Pulmatrix provided a status update on its pending merger with Eos SENOLYTIX, noting that the SEC has declared its Form S-4 registration statement effective and stockholders have approved the deal. The company expects the merger to close by the end of 2026, subject to Nasdaq listing approval and a planned reverse stock split.

Counterparty
Eos SENOLYTIX, Inc.

“Our focus in the third quarter and beyond has been to advance steps towards completing the proposed merger with Eos SENOLYTIX, a privately held biotechnology company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases using the MitoXcel™ platform. To that end, we have obtained SEC effectiveness on our registration statement on Form S-4 in relation to the merger as well as approval from our stockholders on the proposed merger. We anticipate closing the proposed merger by the end of the year.”

Peter Ludlum, Interim Chief Executive Officer of Pulmatrix
9:25 AM ET 8-K
Regulatory Approval Edesa Biotech, Inc. EDSA

Edesa Biotech Regulatory Approval

Edesa Biotech announced that the European Commission has granted orphan designation to its investigational drug paridiprubart for the treatment of Acute Respiratory Distress Syndrome (ARDS). The designation provides regulatory incentives including reduced development fees and potential market exclusivity for up to 10 years following approval.

Counterparty
European Commission
Term
10 years
9:25 AM ET 8-K
M&A Deal Olin Corp OLN

Olin M&A Deal with Huntsman Corporation

Olin Corporation provided a status update on its pending merger with Huntsman Corporation, announcing the leadership structure and divisional organization for the combined entity, OlinHuntsman. The company appointed Philip M. Lister as CFO and established a four-division structure (Essential Chemicals, Polyurethanes, Advanced Solutions, and Winchester), with the merger expected to close in the first quarter of 2027.

Counterparty
Huntsman Corporation
9:18 AM ET 8-K
M&A Deal Integer Holdings Corp ITGR

Integer Holdings M&A Deal with Armstrong Parent, Inc.

Integer Holdings Corporation completed its merger with Armstrong Parent, Inc., an affiliate of KKR, becoming a wholly owned subsidiary. Shareholders of Integer are entitled to receive $127.00 in cash per share. In connection with the closing, the company entered into a new $2.1 billion credit agreement and issued supplemental indentures for its outstanding convertible senior notes.

Counterparty
Armstrong Parent, Inc.
9:12 AM ET 8-K
Nasdaq/NYSE Compliance Notice Tomi Environmental Solutions, Inc. TOMZ

Tomi Environmental Solutions Nasdaq/NYSE Compliance Notice

TOMI Environmental Solutions has regained compliance with Nasdaq's minimum bid price and stockholders' equity requirements, allowing its common stock to continue listing under the symbol 'TOMZ'. The company will be subject to a one-year discretionary monitor by the Nasdaq Hearings Panel beginning September 2, 2026, during which any subsequent noncompliance with equity requirements will result in immediate delisting.

Counterparty
Nasdaq
Term
1 year
9:01 AM ET 8-K
Clinical Trial Data MetaVia Inc. MTVA

MetaVia Clinical Trial Data

MetaVia announced the completion of the final patient visit in its Phase 1 Part 3A study of DA-1726, a dual GLP-1/glucagon receptor agonist. The company also highlighted interim Part 3B data showing a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss, with full data from both parts expected in Q1 2027.

9:01 AM ET 8-K
Clinical Trial Data Maia Biotechnology, Inc. MAIA

Maia Biotechnology Clinical Trial Data

MAIA Biotechnology reported updated interim efficacy data from Part C of its Phase 2 THIO-101 expansion trial evaluating ateganosine (THIO) in patients with advanced non-small cell lung cancer (NSCLC). The trial demonstrated an 88% disease control rate (DCR) in third-line patients who had progressed after prior immunotherapy and chemotherapy, significantly higher than the 25-35% DCR typically seen with standard chemotherapy.

8:46 AM ET 8-K
M&A Deal MongoDB, Inc. MDB

MongoDB M&A Deal with Firebolt Analytics Inc.

MongoDB, Inc. has acquired Firebolt Analytics Inc. to integrate its high-performance analytics engine into the MongoDB Intelligent Data Platform. The acquisition aims to enable real-time analytics on live operational data without the need for separate data pipelines, supporting applications and AI agents that require sub-second query responses.

Counterparty
Firebolt Analytics Inc.
8:41 AM ET 8-K
M&A Deal Axalta Coating Systems Ltd. AXTA

Axalta Coating Systems M&A Deal with Akzo Nobel N.V.

Axalta Coating Systems provided a status update on its pending merger of equals with AkzoNobel, specifically furnishing pro forma financial information related to a notes offering by an AkzoNobel subsidiary. The combined company, to be known as MergeCo, will be parented by AkzoNobel, with the merger remaining subject to final regulatory approvals and customary closing conditions.

Counterparty
Akzo Nobel N.V.
8:31 AM ET 8-K
M&A Deal Air Industries Group AIRI

Air Industries Group M&A Deal with Tenax Aerospace Acquisitions, LLC

Air Industries Group (AIRI) issued a press release disavowing financial illustrations and combined company projections released by its merger partner, Tenax Aerospace Acquisitions, LLC. The company stated that the information was released without its prior review or consent and that stockholders should not rely on the unauthorized pro forma data. The filing serves as a status update on the pending merger, noting that AIRI has not yet verified Tenax's financial results or provided its own 2026 estimates for the illustrations.

Counterparty
Tenax Aerospace Acquisitions, LLC
8:31 AM ET 8-K
Contract Win Ainos, Inc. AIMD

Ainos Wins $9M Contract from ASE Technology Holding Co., Ltd.

Ainos, Inc. signed a $9 million purchase agreement with ASE Technology Holding Co., Ltd. for 5,000 units of its AI NOSE equipment, marking the largest order in the company's history. ASE will pay a 50% deposit ($4.5 million) within 60 days, with the remaining balance due upon delivery completion. The agreement also includes ongoing annual maintenance fees for platform usage and technical updates.

Value
$9M
Counterparty
ASE Technology Holding Co., Ltd.
7:31 AM ET 8-K
Divestiture Tucows Inc TCX

Tucows Divestiture to Point Broadband Acquisition, LLC

Tucows subsidiary Ting Fiber, LLC entered into a definitive agreement to sell Ting Holdco LLC, which includes its owned fiber markets and related securitized debt, to Point Broadband Acquisition (Clearwave). The transaction involves a nominal cash purchase price of $1.00 but will remove approximately $301.5 million in securitized debt from Tucows' consolidated balance sheet, advancing the company's shift toward a capital-light portfolio.

Counterparty
Point Broadband Acquisition, LLC
7:21 AM ET 8-K
M&A Deal Crona Corp. CRONA

Crona M&A Deal with EC Journey Sdn. Bhd.

Crona Corp. completed the acquisition of 100% of the issued and outstanding ordinary shares of EC Journey Sdn. Bhd., a private limited company in Malaysia. The acquisition was completed without monetary consideration as the target was a dormant entity. Crona Corp. intends to use the new wholly owned subsidiary to develop software-related business activities.

Counterparty
EC Journey Sdn. Bhd.
7:15 AM ET 8-K
Clinical Trial Data Sellas Life Sciences Group, Inc. SLS

Sellas Life Sciences Group Clinical Trial Data

SELLAS announced positive topline results from its pivotal Phase 3 REGAL trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML). The trial met its primary endpoint of overall survival, showing a 41% reduction in the risk of death with a median OS of 24.0 months for GPS versus 14.7 months for best available treatment. The company plans to meet with the FDA to discuss the regulatory path forward for a Biologics License Application (BLA) submission.

7:04 AM ET 8-K
M&A Deal UL Solutions Inc. ULS

UL Solutions Signs $350M M&A Deal with Worldly Holdings Inc.

UL Solutions Inc. has entered into a definitive agreement to acquire Worldly Holdings Inc., a supply chain intelligence software company, for an aggregate consideration of $350 million. The deal will be funded through a mix of cash, revolving credit, and approximately $127 million in Class A common stock. To offset the dilution from the stock issuance, UL Solutions also agreed to repurchase $130 million of its Class B common stock from its majority shareholder, UL Standards & Engagement.

Value
$350M
Counterparty
Worldly Holdings Inc.

“This acquisition will build on our supply chain intelligence capabilities and our expanding role in digital trust, helping customers gain greater visibility into where and how their products are made.”

Jennifer Scanlon, President and CEO
7:01 AM ET 8-K
Capital Raise Fact II Acquisition Corp. FACT

Fact II Acquisition Capital Raise of $189M

FACT II Acquisition Corp. provided an update on its trust account balance, which stood at approximately $189.38 million as of November 16, 2026. This results in an updated estimated redemption price of $10.82 per share for shareholders ahead of an upcoming extraordinary general meeting to vote on an extension.

Value
$189M
6:56 AM ET 8-K
M&A Deal Ftai Infrastructure Inc. FIP

Ftai Infrastructure Signs $255M M&A Deal with DRUbit Holdings LLC

FTAI Infrastructure's subsidiary, Drub LLC, completed the acquisition of DRUbit LLC from DRUbit Holdings LLC for an enterprise value of $255 million. As part of the transaction, the company assumed an existing $183.6 million secured term loan facility maturing in 2031 and entered into a new bridge loan credit agreement to fund the acquisition.

Value
$255M
Counterparty
DRUbit Holdings LLC
6:06 AM ET 8-K
Divestiture Strawberry Fields REIT, Inc. STRW

Strawberry Fields REIT Divestiture for $90M

Strawberry Fields REIT completed the sale of 13 healthcare facilities in Arkansas to an unaffiliated third party for $90.0 million. The company received net cash proceeds of approximately $84.6 million after repaying a $5.1 million mortgage and intends to reinvest the funds via a Section 1031 like-kind exchange.

Value
$90M
6:06 AM ET 8-K
Nasdaq/NYSE Compliance Notice Brand Engagement Network Inc. BNAI

Brand Engagement Network Nasdaq/NYSE Compliance Notice

Brand Engagement Network Inc. notified Nasdaq of its non-compliance with multiple listing rules, including requirements for timely periodic reporting, audit and compensation committee composition, and oversight of related party transactions. The company also identified potential non-compliance regarding shareholder approval for equity compensation arrangements. The company has 45 days to submit a plan to regain compliance, which if accepted, could grant an extension of up to 180 days.

Counterparty
Nasdaq
Term
45 days
6:05 AM ET 8-K
M&A Deal Inflection Point Acquisition Corp. VII IPXG

Inflection Point Acquisition Corp. VII Signs $70M M&A Deal with Elroy Air, Inc.

Inflection Point Acquisition Corp. VII (IPXG) provided a status update on its pending merger target, Elroy Air, which has signed a $70 million aircraft purchase agreement with Barq Group. The deal includes a firm order for five Chaparral cargo drones and 15 production slot reservations, supported by a $10.25 million initial deposit. This update follows the previously announced business combination agreement between Inflection Point and Elroy Air.

Value
$70M
Counterparty
Elroy Air, Inc.
6:03 AM ET 8-K/A
M&A Deal Evernorth Holdings Inc. XRPN

Evernorth Holdings M&A Deal with Pathfinder Digital Assets LLC

Evernorth Holdings Inc. filed an amendment to its original 8-K to provide required financial statements and pro forma information following the completion of its business combination with Pathfinder Digital Assets LLC and Arrington Capital SPAC I Inc. The merger was consummated on October 9, 2026, resulting in Evernorth becoming the public successor entity. The filing includes Pathfinder's unaudited financial statements showing a net loss of $3.73 million for the nine months ended September 30, 2026.

Counterparty
Pathfinder Digital Assets LLC
6:34 PM ET 8-K
M&A Deal Aon plc AON

Aon Signs $17B M&A Deal with Usi

Aon plc has completed its $17.0 billion acquisition of USI, a leading provider of property and casualty and employee benefit solutions for the middle market. The deal establishes a premier U.S. middle-market platform and integrates USI's 10,500 team members and $3 billion in annual revenue into Aon's operations.

Value
$17B
Counterparty
USI

“Today marks an important step forward for our clients, colleagues and shareholders as we welcome USI to the Aon family and formally establish the premier U.S. middle-market platform.”

Greg Case, CEO of Aon

“With Aon’s distinctive capabilities and integrated, one-firm platform, we are entering an exciting new chapter for our colleagues and clients.”

Mike Sicard, President of Aon and global CEO of the middle market
6:34 PM ET 8-K
M&A Deal Hormel Foods Corp HRL

Hormel Foods Signs $700M M&A Deal with Brakebush Brothers, LLC

Hormel Foods Corporation completed its acquisition of Brakebush Brothers, LLC on November 16, 2026. To fund the transaction, the company entered into a $1.0 billion delayed draw term loan facility and immediately borrowed $700 million to pay a portion of the purchase price.

Value
$700M
Counterparty
Brakebush Brothers, LLC
6:34 PM ET 8-K
M&A Deal Endra Life Sciences Inc. NDRA

Endra Life Sciences Signs $50M M&A Deal with Noble Africa LLC

ENDRA Life Sciences provided a status update on its pending merger with Noble Africa LLC, a subsidiary of ASP Isotopes Inc. The transaction, which includes a concurrent $50 million private placement, will result in Noble Africa becoming a wholly owned subsidiary and ENDRA being renamed 4K Resources Inc.

Value
$50M
Counterparty
Noble Africa LLC

“Our focus during the third quarter remained on completing the proposed merger with Noble Africa while managing ENDRA’s operating resources and liquidity to support transaction-related priorities.”

Alexander Tokman, Chairman and Chief Executive Officer of ENDRA Life Sciences

“The proposed transaction represents an important strategic opportunity for our stockholders. We continue to work with our merger counterparties to complete the remaining steps necessary to close the merger.”

Alexander Tokman, Chairman and Chief Executive Officer of ENDRA Life Sciences
4:46 PM ET 8-K
Clinical Trial Data iBio, Inc. IBIO

iBio Clinical Trial Data

iBio announced extended preclinical data from a non-human primate study of IBIO-610, showing a 2.3% reduction in body weight and significant fat mass reduction over 28 weeks while maintaining lean mass. The company also disclosed preclinical data for its amylin program demonstrating selective receptor activation and reduced food intake in rat models. These results highlight the efficacy of iBio's AI-enabled antibody discovery platform in targeting obesity and cardiometabolic diseases.

4:46 PM ET 8-K
Nasdaq/NYSE Compliance Notice Cable One, Inc. CABO

Cable One Nasdaq/NYSE Compliance Notice

Cable One received a deficiency notice from the NYSE because its average global market capitalization and stockholders' equity both fell below the $50 million minimum requirement. The company has 45 days to submit a plan to regain compliance within an 18-month cure period. Additionally, the company disclosed it missed a $10 million interest payment on its 4.00% senior notes due 2030, entering a 30-day grace period.

Counterparty
New York Stock Exchange
Term
18 months
4:46 PM ET 8-K
Capital Raise Zoomcar Holdings, Inc.

Zoomcar Holdings Capital Raise

Zoomcar Holdings completed the eighth closing of its private placement, issuing 100 Series A units for gross proceeds of $100,000. Each unit consists of one share of Series A Convertible Preferred Stock and a warrant to purchase 20,000 shares of common stock. The company has extended the termination date of the overall $5 million offering (plus a $5 million overallotment option) to November 30, 2026.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.